Role of blood parametersin ovarian masses
- Conditions
- Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
- Registration Number
- CTRI/2023/03/050555
- Lead Sponsor
- AIIMS RISHIKESH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
The study is designed to include retrospective data on benign and
malignant ovarian masses operated from January 2019 till the data of
study initiation. It also includes prospective data on benign and
27
malignant ovarian masses who will be operated during an 18-month
period since the study initiation.
1. Those underwent radiotherapy, chemotherapy, targeted drugs, or
other anti-tumour therapy prior to surgery
2. had a history of autoimmune diseases or other malignancies
3. had incomplete blood investigation and operative findings
4. Patients with clinical infectious diseases who had a high WBC count
5. Patients with systemic diseases affecting WBC and platelet counts
such as immunodeficiency and splenectomy
6. Had borderline ovarian cancer
7. Had undergone any surgery on ovary predominantly at an earlier
age
8. Pregnancy with ovarian masses
9. Ovarian masses planned for conservative management
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method